IL6 and COVID-19: Some reports show that patients with severe COVID-19 mount a robust IFN response; therefore, severe disease is likely due to overproduction of cytokines, such as TNF-α and interleukins such as IL-1 and IL-6 which opens the therapeutic window to a generic immunological dampener such as corticosteroids (30).